Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 2/20 | 1.00 |
| ▸ | CDC25B | P30305 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vitamin E Quinone SCHEMBL3216957 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3216875 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3220210 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3045967 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3045963 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL17024163 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3216945 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL1186492 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL20683220 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 | |
| Vitamin E Quinone SCHEMBL3220204 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2CDC25BALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344142-B1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS INC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | claimed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | claimed |
| EP-2344142-B1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3827815-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC Therapeutics, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210128494-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | BIOELECTRON TECHNOLOGY CORPORATION | 2021-05-06 | — | — | US | disclosed |
| US-10736857-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | PTC THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190083419-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10105325-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9399612-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969420-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-8653144-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314153-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-10105325-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, DDT, ADH4 | PTPN1 2108/4885PTPN2 2060/4885CDC25B 4487/4885 |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-10736857-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-20190083419-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
| US-20210128494-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.